Current state of adjuvant therapy in resected pancreatic adenocarcinoma

References

• Delcore R, Rodriguez FJ, Forster J, Hermreck AS, Thomas JH. Significance of lymph node metastases in patients with pancreatic cancer undergoing curative resection. Am J Surg 1996; 172: 463–8; discussion 468–9
   PubMedGoogle Scholar
• Yeo CJ, Abrams RA, Grochow LB, Sohn TA, Ord SE, Hruban RH, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective single-institution expeerience. Ann Surg 1997; 225: 621–33
   PubMed Web of Science ®Google Scholar
• Gouma DJ, van Geenen RC, van Gulik TM, de Haan RJ, de Wit LT, Busch OR, et al. Rates of complications and death after pancreaticoduodenectomy: Risk factors and the impact of hospital volume. Ann Surg 2000; 232: 786–95
   PubMed Web of Science ®Google Scholar
• Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, et al. Resected adenocarcinoma of the pancreas – 616 patients: Results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4: 567–79
   PubMed Web of Science ®Google Scholar
• Yeo CJ, Cameron JL, Lillemoe KD, Sohn TA, Campbell KA, Sauter PK, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: Randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg 2002; 236: 355–66; discussion 366–8
   PubMedGoogle Scholar
• Richter A, Niedergethmann M, Sturm JW, Lorenz D, Post S, Trede M. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg 2003; 27: 324–9
   PubMed Web of Science ®Google Scholar
• Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler MW. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 2004; 91: 586–94
   PubMed Web of Science ®Google Scholar
• Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993; 165: 68–72; discussion 72–3
   PubMed Web of Science ®Google Scholar
• Nitecki SS, Sarr MG, Colby TV, van Heerden JA. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving?. Ann Surg 1995; 221: 59–66
   PubMed Web of Science ®Google Scholar
• Allema JH, Reinders ME, van Gulik TM, Koelemay MJ, Van Leeuwen DJ, de Wit LT, et al. Prognostic factors for survival after pancreaticoduodenectomy for patients with carcinoma of the pancreatic head region. Cancer 1995; 75: 2069–76
   PubMedGoogle Scholar
• Mosca F, Giulianotti PC, Balestracci T, Di Candio G, Pietrabissa A, Sbrana F, et al. Long-term survival in pancreatic cancer: Pylorus-preserving versus Whipple pancreatoduodenectomy. Surgery 1997; 122: 553–66
   PubMed Web of Science ®Google Scholar
• Allison DC, Piantadosi S, Hruban RH, Dooley WC, Fishman EK, et al. DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma. J Surg Oncol 1998; 67: 151–9
   PubMed Web of Science ®Google Scholar
• Harrison LE, Klimstra DS, Brennan MF. Isolated portal vein involvement in pancreatic adenocarcinoma. A contraindication for resection?. Ann Surg 1996; 224(3)342–7; discussion 347–9
   PubMedGoogle Scholar
• Leach SD, Lee JE, Charnsangavej C, Cleary KR, Lowy AM, Fenoglio CJ, et al. Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head. Br J Surg 1998; 85: 611–7
   PubMedGoogle Scholar
• Pedrazzoli S, DiCarlo V, Dionigi R, Mosca F, Pederzoli P, Pasquali C, et al. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: A multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg 1998; 228: 508–17
   PubMed Web of Science ®Google Scholar
• Staley CA, Lee JE, Cleary KR, Abbruzzese JL, Fenoglio CJ, Rich TA, et al. Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Am J Surg 1996; 171: 118–24; discussion 124–5
   PubMed Web of Science ®Google Scholar
• Moertel CG, Childs DS, Jr, Reitemeier RJ, Colby MY, Jr, Holbrook MA. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 1969; 2: 865–7
   PubMed Web of Science ®Google Scholar
• Tepper J, Nardi G, Suit H. Carcinoma of the pancreas: Review of MGH experience from 1963 to 1973: Analysis of surgical failure and inplication for radiation therapy. Cancer 1976; 37: 1519–24
   PubMed Web of Science ®Google Scholar
• Pilepich MV, Miller HH. Preoperative irradiation in carcinoma of the pancreas. Cancer 1980; 46: 1945–49
   PubMed Web of Science ®Google Scholar
• Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ, Rubin J, et al. Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 1981; 48: 1705–10
   PubMed Web of Science ®Google Scholar
• Kopelson G. Curative surgery for adenocarcinoma of the pancreas/ampulla of Vater: The role of adjuvant pre- or postoperative radiation therapy. Int J Radiat Oncol Biol Phys 1983; 9: 911–15
   PubMed Web of Science ®Google Scholar
• Kalser MH, Ellenberg SS. Pancreatic Cancer. Adjuvant combined radiation and chemotherapy following curative radiation. Arch Surg 1985; 120: 899–903
   PubMed Web of Science ®Google Scholar
• The Gastrointestinal Tumor Study Group (GITSG). Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987;59:2006–10.
   PubMedGoogle Scholar
• Yeo CJ, Cameron JL, Lillemoe K, Sitzmann JV, Hruban RH, Goodman SN, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 1995; 221: 721–31
   PubMed Web of Science ®Google Scholar
• Whittington R, Bryer MP, Haller DG, Solin LJ, Rosato EF. Adjuvant therapy of resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 1991; 21: 1137–43
   PubMedGoogle Scholar
• Foo ML, Gunderson LL, Nagorney DM, McLlrath DC, van Heerden JA, Robinow JS, et al. Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation + / − 5 fluorouracil. Int J Radiat Oncol Biol Phys 1993; 26: 483–9
   PubMed Web of Science ®Google Scholar
• Abrams RA, Grochow LB, Chakravarthy A, Sohn TA, Zahurak ML, Haulk TL, et al. Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: Survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels. Int J Radiat Oncol Biol Phys 1999; 44: 1039–46
   PubMed Web of Science ®Google Scholar
• Paulino AC. Resected pancreatic cancer treated with adjuvant radiotherapy with or without 5-fluorouracil: Treatment results and patterns of failure. Am J Clin Oncol 1999; 22: 489–94
   PubMed Web of Science ®Google Scholar
• Mehta VK, Fisher GA, Ford JM, Oberhelman HA, Vierra MA, Bastidas AJ, et al. Adjuvant radiotherapy and concomitant 5-Fluorouracil by protracted venous infusion for resected pancreatic cancer. Int J Radiat Oncol Biol Phys 2000; 48: 1483–7
   PubMed Web of Science ®Google Scholar
• Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999; 230: 776–82; discussion 782–4
   PubMed Web of Science ®Google Scholar
• Regine WF, John WJ, Mohiuddin M. Evolving trends in combined modality therapy for pancreatic cancer. J Hepatobiliary Pancreat Surg 1998; 5: 227–34
   PubMedGoogle Scholar
• Bakkevold KE, Arnesjo B, Dahl O, Kambestad B. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater – results of a controlled, prospective, randomized multicentre study. Eur J Cancer 1993; 29A: 698–703
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, et al. European Study Group for Pancreatic Cancer. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: A randomised controlled trial. Lancet 2001; 358: 1576–85
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Stokken DD, Dunn JA, Almond J, Beger HG, Pederzoli P, et al. European Study Group for Pancreatic Cancer. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001; 234: 758–68
   PubMed Web of Science ®Google Scholar
• Raraty MG, Magee CJ, Ghaneh P, Neoptolemos JP. New techniques and agents in the adjuvant therapy of pancreatic cancer. Acta Oncol 2002; 41(7–8)582–95. Review
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Stokken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Eng J Med 2004; 350: 1200–10
   PubMed Web of Science ®Google Scholar
• Choti MA. Adjuvant therapy for pancreatic cancer – the debate continues. New Engl J Med 2004; 350: 1249–51
   PubMed Web of Science ®Google Scholar
• Koshy MC, Landry JC, Cavanaugh SX, Fuller CD, Willett CG, Abrams RA, et al. A challenge to the therapeutic nihilism of ESPAC-1. Int J Radiat Oncol Biol Phys 2005; 61: 965–6
   PubMed Web of Science ®Google Scholar
• Neuhaus, P, Oettle, H, Post, S, Gellert, K, Ridwelski, H, Schramm, H, et al. Deutsche Krebsgesellschaft. A randomised, prospective, multicenter, phase III trial of adjuvant chemotherapy with gemcitabine vs. observation in patients with resected pancreatic cancer. ASCO Annual Meeting 2005; Abstract LBA4013.
   Google Scholar
• Ishikawa O, Ohigashi H, Sasaki Y, Furukawa H, Kabuto T, Kameyama M, et al. Liver perfusion chemotherapy via both the hepatic artery and portal vein to prevent hepatic metastasis after extended pancreatectomy for adenocarcinoma of the pancreas. Am J Surg 1994; 168: 361–4
   PubMedGoogle Scholar
• Ishikawa O, Ohigashi H, Sasaki Y, Masao K, Kabuto T, Furukawa H, et al. Adjuvant therapies in extended pancreatectomy for ductal adenocarcinoma of the pancreas. Hepatogastroenterology 1998; 45: 644–50
   PubMedGoogle Scholar
• Beger HG, Link KH, Gansauge F. Adjuvant regional chemotherapy in advanced pancreatic cancer: Results of a prospective study. Hepatogastroenterology 1998; 45: 638–43
   PubMedGoogle Scholar
• Beger HG, Link KH, Gansauge F. Intraarterial adjuvant chemotherapy after pancreticoduodenectomy: Significant reduction in occurrence of liver metastasis. World J Surg 1999; 23: 946–9
   PubMedGoogle Scholar
• Ozaki H, Kinoshita T, Kosuge T, Shimada K, Yamamoto J, Tokuuye K, et al. Long-term survival after multimodality treatment for resectable pancreatic cancer. Int J Pancreatol 2000; 27: 217–24
   PubMedGoogle Scholar
• Ishikawa O, Ohigashi H, Teshima T, Chatani M, Inoue T, Tanaka S, et al. Clinical and histopathological appraisal of preoperative irradiation for adenocarcinoma of the pancreatoduodenal region. J Surg Oncol 1989; 40: 143–51
   PubMed Web of Science ®Google Scholar
• Evans DB, Rich TA, Byrd DR, Ames FC. Adenocarcinoma of the pancreas: Current management of resectable and locally advanced disease. South Med J 1991; 84: 566–70
   PubMedGoogle Scholar
• Yeung RS, Weese JL, Hoffman JP, Solin LJ, Paul AR, Engstrom PF, et al. Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma. A phase II study. Cancer 1993; 72: 2124–33
   PubMed Web of Science ®Google Scholar
• Coia L, Hoffman J, Scher R, Weese J, Solin L, Weiner L, et al. Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum. Int J Radiat Oncol Biol Phys 1994; 30: 161–7
   PubMed Web of Science ®Google Scholar
• Hoffman JP, Weese JL, Solin LJ, Engstrom P, Agarwal P, Barber LW, et al. A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas. Am J Surg 1995; 169: 71–7
   PubMed Web of Science ®Google Scholar
• Spitz FR, Abbruzzese JL, Lee JE, Pisters PW, Lowy AM, Fenoglio CJ, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 1997; 15: 928–37
   PubMed Web of Science ®Google Scholar
• Pendurthi TK, Hoffman JP, Ross E, Johnson DE, Eisenberg BL. Preoperative versus postoperative chemoradiation for patients with resected pancreatic adenocarcinoma. Am Surg 1998; 64: 686–92
   PubMedGoogle Scholar
• Hoffman JP, Lipsitz S, Pisansky T, Weese JL, Solin L, Benson AB 3rd. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: An Eastern Cooperative Oncology Group Study. J Clin Oncol 1998; 16: 317–23
   PubMed Web of Science ®Google Scholar
• Pisters PW, Abbruzzese JL, Janjan NA, Cleary KR, Charnsangavej, Goswitz MS, et al. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol 1998; 16: 3843–50
   PubMed Web of Science ®Google Scholar
• Snady H, Bruckner H, Cooperman A, Paradiso J, Kiefer L. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer 2000; 89: 314–27
   PubMed Web of Science ®Google Scholar
• Breslin TM, Hess KR, Harbison DB, Jean ME, Cleary KR, Dackiw AP, et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: Treatment variables and survival duration. Ann Surg Oncol 2001; 8: 123–32
   PubMed Web of Science ®Google Scholar
• Pisters PW, Wolff Ra, Janjan NA, Cleary KR, Changsangavej C, Crane CN, et al. Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: Toxicities, histologic response rates, and event-free outcome. J Clin Oncol 2002; 20: 2537–44
   PubMed Web of Science ®Google Scholar
• White R, Lee C, Anscher M, Gottfried M, Wolff R, Keogan M, et al. Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas. Ann Surg Oncol 1999; 6: 38–45
   PubMedGoogle Scholar
• White RR, Paulson EK, Freed KS, Keogan MT, Hurwitz HI, Lee C, et al. Staging of pancreatic cancer before and after neoadjuvant chemoradiation. J Gastrointest Surg 2001; 5: 626–33
   PubMed Web of Science ®Google Scholar
• White RR, Hurwitz HI, Morse MA, Lee C, Anscher MS, Paulson EK, et al. Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol 2001; 8: 758–65
   PubMed Web of Science ®Google Scholar
• Sindelar WF, Kinsella TJ. Studies of intraoperative radiotherapy in carcinoma of the pancreas. Ann Oncol 1999; 10(Suppl 4)226–30
   PubMedGoogle Scholar
• Zerbi A, Fossati V, Parolini D, Carlucci M, Balzano G, Bordogna G, et al. Intraoperative radiation therapy adjuvant to resection in the treatment of pancreatic cancer. Cancer 1994; 73: 2930–5
   PubMed Web of Science ®Google Scholar
• Fossati V, Cattaneo GM, Zerbi A, Galli L, Bordogna G, Reni M, et al. The role of intraoperative therapy by electrone beam and combination of adjuvant chemotherapy and external radiotherapy in carcinoma of the pancreas. Tumori 1995; 81: 23–31
   PubMed Web of Science ®Google Scholar
• Di Carlo V, Zerbi A, Balzano G, Villa E. Intraoperative and postoperative radiotherapy in pancreatic cancer. Int J Pancreatol 1997; 21: 53–8
   PubMed Web of Science ®Google Scholar
• Hosotani R, Kogire M, Arii S, Nishimura Y, Hiraoka M, Imamura M. Results of pancreatectomy with radiation therapy for pancreatic cancer. Hepatogastroenterology 1997; 44: 1528–35
   PubMedGoogle Scholar
• Sunamura M, Kobari M, Lozonschi L, Egawa S, Matsuno S. Intraoperative radiotherapy for pancreatic adenocarcinoma. J Hepatobiliary Pancreat Surg 1998; 5: 151–6
   PubMedGoogle Scholar
• Kokubo M, Nishimura Y, Shibamoto Y, Sasai K, Kanamori S, Hosotani R, et al. Analysis of the clinical benefit of intraoperative radiotherapy in patients undergoing macroscopically curative resection for pancreatic cancer. Int J Radiat Oncol Biol Phys 2000; 48: 1081–7
   PubMedGoogle Scholar
• Alfieri S, Morganti AG, Di Giorgio A, Valentini V, Bossola M, Trodella L, et al. Improved survival and local control after intraoperative radiation therapy and postoperative radiotherapy: A multivariate analysis of 46 patients undergoing surgery for pancreatic head cancer. Arch Surg 2001; 136: 343–7
   PubMedGoogle Scholar
• Reni M, Panucci MG, Ferreri AJ, Balzano G, Passoni P, Cattaneo GM, et al. Effect on local control and survival of electron beam intraoperative irradiation for resectable pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys 2001; 50: 651–8
   PubMedGoogle Scholar
• Abrams RA, Lillemoe KD, Piantadosi S. Continuing controversy over adjuvant therapy of pancreatic cancer. Lancet 2001; 358: 1565
   PubMed Web of Science ®Google Scholar
• Glimelius B. Has progress been made in gastrointestinal cancer treatment?. Acta Oncol 2002; 41: 115–7
   PubMed Web of Science ®Google Scholar
• Ishikawa O, Ohigashi H, Imaoka S, Teshima T, Inoue T, Sasaki Y, et al. Concomitant benefit of preoperative irradiation in preventing pancreas fistula formation after pancreatoduodenectomy. Arch Surg 1991; 126: 885–9
   PubMedGoogle Scholar
• Lowy AM, Lee JE, Pisters PW, Davidson BS, Fenoglio CJ, Stanford P, et al. Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease. Ann Surg 1997; 226: 632–41
   PubMed Web of Science ®Google Scholar
• Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997; 15: 2403–13
   PubMed Web of Science ®Google Scholar
• Permert, J, Hafstrom, L, Nygren, P, Glimelius, B, SBU-group. A systematic overview of chemotherapy effects in pancreatic cancer. Acta Oncol 2001;40((2–3)):361–70.
   PubMedGoogle Scholar
• Van Laethem JL, Demols A, Gay F, Closon MT, Collette M, Polus M, et al. Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: A phase II study. Int J Radiat Oncol Biol Phys 2003; 56: 974–80
   PubMedGoogle Scholar
• Willett, CG, Safran, H, Abrams, RA, Regine, WF, Rich, TA, Gastrointestinal Committee of the Radiation Therapy Oncology Group. Clinical research in pancreatic cancer: The Radiation Therapy Oncology Group trials. Int J Radiat Oncol Biol Phys 2003;56((4 Suppl)):31–7.
   PubMedGoogle Scholar
• Nukui Y, Picozzi VJ, Traverso LW. Interferon-based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 2000; 179: 367–71
   PubMed Web of Science ®Google Scholar
• Louvet C, Andre T, Lledo G, Hammel P, Bleiberg H, Bouleuc C, et al. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: Final results of a GERCOR multicenter phase II study. J Clin Oncol 2002; 20(6)1512–8
   PubMed Web of Science ®Google Scholar
• Alberts SR, Townley PM, Goldberg RM, Cha SS, Moore DF, Jr, Krook JE, et al. Gemcitabine and oxaliplatin for patients with advanced or metastatic pancreatic cancer: A North Central Cancer Treatment Group (NCCTG) phase I study. Ann Oncol 2002; 13: 553–7
   PubMed Web of Science ®Google Scholar
• Ducreux M, Mitry E, Ould-Kaci M, Boige V, Seitz JF, Bugat R, et al. Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. Ann Oncol 2004; 15: 467–73
   PubMed Web of Science ®Google Scholar